Generic Name and Formulations:
Tazarotene 0.1%; foam.
Stiefel Laboratories, Inc.
Indications for FABIOR:
Cleanse and dry affected area. Apply a thin layer to affected areas on face and/or upper trunk once daily in the PM. Women of childbearing potential: begin therapy during normal menses.
Obtain reliable negative pregnancy test within 2 weeks before starting therapy; use effective contraception during therapy. Do not use on broken or eczematous skin. History of local hypersensitivity. Photosensitivity. History of skin cancer. Avoid eyes, lips, mouth, mucous membranes, sun and UV light; use adequate sun protection. Increased irritation in extreme weather. Discontinue if excessive local irritation occurs. Flammable. Nursing mothers: not recommended.
Cumulative irritant effect with concomitant other topical acne therapy; use caution. Avoid use until the effects of strong topical drying agents have subsided. Concomitant oxidizing agents (eg, benzoyl peroxide) may cause tazarotene degradation and reduce efficacy; apply at different times of the day (eg, AM & PM) if combination treatment is needed.
Application site reactions (eg, irritation, dryness, erythema, exfoliation, pain, photosensitivity, pruritus, dermatitis).
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Nomophobia: The Modern-Day Pathology
- Emerging Theories in the Pathophysiology of MDD: Could the Opioid System Be Involved?
- Attention-Deficit/Hyperactivity Disorder Increasing Among US Children and Adolescents
- Combination Cognitive Behavioral Therapy With Fluoxetine Effective for Adolescent Depression
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Suicide Attempt Risk Among LGB Populations Higher Than Previously Estimated
- Residents Should Take Advantage of Paid Time Off
- Outpatient Engagement May Lower Suicide Attempts in Patients With Fibromyalgia
- Prevalence of Alzheimer Disease, Related Dementia Set to Double
- Forms of Childhood Adversity Related to First-Episode Psychosis Outcomes